Abstract
The neurotoxic side-effects of cisplatin affect predominantly the large, myelinated fibres of peripheral nerves, leading to a sensory neuropathy. Several reports of cisplatin-associated autonomic neuropathy have been published. Autonomic dysfunction however, is caused by a neuropathy of small unmyelinated nerve fibres.
By using the absolute pupil diameter as a parameter of autonomic nervous system function, we studied autonomic neuropathy in the eye of cisplatin-intoxicated rats. In addition, we examined autonomic cardiovascular function by measuring the change in heart rate (HR) and mean arterial blood pressure (MAP) in response to intravenous phenylephrine (PHE) and tyramine (TYR). No significant differences in mean pupil diameter developed in cisplatin-intoxicated rats (n = 12) in the course of 9 weeks (total cumulative dose cisplatin 18 mg/kg) compared with normal controls (n = 9) (MANOVA, F1,19 = 0.88, P < 0.36). The PHE- and TYR-induced changes in MAP and HR were virtually the same in cisplatin-intoxicated rats when compared with normal controls.
We conclude that cisplatin probably does not cause autonomic dysfunction, at least not in rats, in doses commonly used and which are known to cause a peripheral, sensory neuropathy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Hansen SW: Autonomic neuropathy after treatment with cisplatin, vinblastine, and bleomycin for germ cell cancer. BMJ 300: 511–512, 1990.
Rosenfeld CS, Broder LE: Cisplatin-induced autonomic neuropathy. Cancer Treatm Rep 68: 659–660, 1984.
Cohen SC, Mollman JE: Cisplatin-induced gastric paresis. J Neuro-Oncol 5: 237–240, 1987.
Richardson P, Cantwell BM: Autonomic neuropathy after cisplatin based chemotherapy. BMJ 300: 1466–1467, 1990.
Boogerd W, Ten Bokkel Huinink WW, Dalesio O, Hoppenbrouwers WJJF, Van Der Sande JJ: Cisplatin-induced neuropathy: central, peripheral and autonomic nerve involvement. J Neuro-Oncol 9: 255–263, 1990.
De Koning P, Neijt JP, Jennekens FGI, Gispen WH: Evaluation of cis-diaminechloroplatinum (II) (cisplatin) neurotoxicity in rat. Toxicol Appl Pharmacol 89: 81–87, 1987.
Vandertop WP, De Vries WB, Notermans NC, Tulleken CAF, Gispen WH: Beneficial effect of an ACTH4–9, analogue on experimentally induced diabetic autonomic neuropathy in the eye of the rat under general anaesthesia. J Anton Nerv Syst 51: 49–51, 1995.
Vandertop WP, De Vries WB, Notermans NC, Tulleken CAF, Gispen WH: Experimentally induced autonomic neuropathy. Beneficial effect of a systemic ACTH4–9 analogue on oculomotor nerve regeneration. Rest Neurol Neurosc 7: 37–43, 1994.
Vandertop WP, De Vries WB, Notermans NC, Tulleken CAF, Gispen WH: Experimentally induced autonomic neuropathy. Beneficial effect of a topical ACTH4–9 analogue on oculomotor nerve regeneration. Neurosurgery 35: 457–462, 1994.
Bland JM, Altman DG: Statistical methods for assessing agreement between two methods of clinical measurement. Lancet: 307–310,1986.
Krarup-Hansen A, Fugleholm K, Helweg-Larsen S, Hauge EN, Schmalbruch H, Trojaborg W, Krarup C: Examination of distal involvement in cisplatin-induced neuropathy in man. An electrophysiological and histological study with particular reference to touch receptor function. Brain 116: 1017–1041, 1993.
Hamers FPT, Gispen WH, Neijt JP: Neurotoxic side-effects of cisplatin. Eur J Cancer 27: 372–376, 1991.
Hamers FPT, Pette C, Bravenboer B, Vecht CJ, Neijt JP, Gispen WH: Cisplatin-induced neuropathy in mature rats. Effects of the melanocortin-derived peptide ORG 2766. Cancer Chemother. Pharmacol 32: 162–166, 1993.
Jackson CV, Carrier GO: Influence of short-term experimental diabetes on blood pressure and heart rate in response to norepinephrine and angiotensin II in the conscious rat. J Cardiovasc Pharmacol 5: 260–265, 1983.
Van Der Zee CEEM, Brakkee JH, Gispen WH: Beneficial effect of Org 2766 treatment on peripheral neuropathy and blood pressure response to tyramine in streptozotocin-induced diabetic rats. Eur J Pharmacol 147: 237–246, 1988.
Low PA: Quantitation of autonomic responses. In: Dyck PJ, Thomas PK, Lambert EH, Bunge R (eds) Peripheral Neuropathy. WB Saunders, Philadelphia, 1984, pp 1139–1165.
Goodman and Gilman's The Pharmacological Basis of Therapeutics. 8th edition. Macmillan Publishing Company: New York, Toronto, London, 1990, pp 207.
Gerritsen Van Der Hoop R, Vecht CJ, Van Der Burg MEL, Elderson A, Boogerd W, Heimans JJ, Vermorken J, Jennekens FGI, Van Houwelingen JC, Gispen WH, Neijt JP: Prevention of cisplatin neurotoxicity with an ACTH (4–9) analogue in patients with ovarian cancer. NEJM 322: 89–94, 1990.
Thompson SW, Davis LE, Kornfeld M, Hilgers RD, Standefer JC: Cisplatin neuropathy. Cancer 54: 1269–1275, 1984.
Elderson A, Gerritsen Van Der Hoop R, Haanstra W, Neijt JP, Gispen WH, Jennekens FGI: Vibration perception and thermoperception as quantitative measurements in the monitoring of cisplatin-induced neurotoxicity. J Neurol Sci 93: 167–174, 1989.
Cho ES: Toxic effects of adriamycin in the ganglia of the peripheral nervous system: a neuropathological study. J Neuropath Exp Neurol 36: 907–915, 1977.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Vandertop, W.P., de Vries, W.B., Notermans, N.C. et al. Cisplatin-induced autonomic neuropathy: does it really exist?. J Neuro-Oncol 27, 53–60 (1996). https://doi.org/10.1007/BF00146084
Issue Date:
DOI: https://doi.org/10.1007/BF00146084